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Abstract: 
Hyperlipidemia is one of the most important factors leading  to atherosclerosis and heart disease, therefore,  this 
study conducted to examine the effect of two newly synthesized compounds[3-(5-(ethylthio)-1,3,4-thiadiazol-2-
yl)-2,3-dihydro-2-(3-nitrophenyl)benzo[1-3-e] thiazin-4-one (I) and 5(4-dimethyl amino) benzylidene amino)-
1,3,4-thiadiazole-2-thiol(II)] on the activities of creatine kinase(CK) and 3-hydroxy-3-methylglutaryl- CoA 
reductase (HMG-CoA redutase) in serum of hyperlipidemic patients in vitro study. Also to determine the type of 
inhibition of these compounds on the above enzymes which may be used as lipid lowering agents in future. The 
results revealed that compound I showed the best inhibition effect at 10-4 M concentration, while compound II 
showed the best inhibition effect at 10-5M concentration for both enzymes. The effect of compound I on CK 
activity was found to be noncompetitive inhibitor with Vmax values (1000 and 344.82)U/L respectively for the 
uninhibited and inhibited reactions and Km value (10)mmol/L while compound II was found to be competitive 
inhibitor with Vmax value (588.23)U/L and Km values (5.51 and 4)mmol/L respectively for the uninhibited and 
inhibited reactions. Compounds I and II were found to be competitive inhibitors on HMG-CoA reductase with 
Vmax value (0.020)U/L and Km values(0.339 and 0.125)mmol/L respectively for the uninhibited  and inhibited 
reactions for compound I and Vmax value (0.021) U/L and Km values(1.111 and 0.256)mmol/L respectively for 
the uninhibited and inhibited reactions for compound II. In conclusion the new compounds(I and II) showed 
different inhibitory effect on CK and HMG-CoA reductase activities that could be used in treatment of 
hyperlipidemia and related disease in future. 
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Introduction: 
   Elevation in the blood lipids termed hyperlipidemia. The increase in cholesterol, TG, LDL-c and reduction 
HDL-c increase atherosclerotic plaque formation resulting in risk of heart attack[1-3]. Investigations into 
vascular consequences of chronic hypercholesterolemia, the mechanisms through which these consequences 
occur, and the potentially beneficial effects of ameliorative therapies have received considerable attention during 
the last decade[4,5]. 
   Creatine Kinase (CK), which catalysis the conversion of creatine and consumes adenosine triphosphate (ATP) 
to create phosphocreatine (PCr) and adenosine diphosphate (ADP), expressed by various tissues and cell types. 
Clinically, creatine kinase is assayed in blood tests as a marker of myocardial infarction (heart attack), 
rhabdomyolysis (severe muscle breakdown), muscular dystrophy, the autoimmune myositis and in acute renal 
failure [6]. 
3-Hydroxy-3-Methyl Glutaryl-CoA Reductase (HMG-CoA reductase) is the rate limiting step in the biosynthesis 
of cholesterol and isopernoides [6,7]. Statin, and its derivatives are HMG-CoA rreductase inhibitors, which used 
for decades in lipid lowering [8,9]. But the high prevalence of their adverse effects such as myopathy  
myotoxicity [10], liver damages enhances anticoagulant effect [11] and potential drug-drug interactions has been 
reported [12]. 
   Schiff bases and thiadiazole the important classes of the most widely used organic compounds which gained 
importance in pharmaceutical fields due to abroad spectrum of biological activities like anti-inflammatory, 
antimicrobial, and antidyslipidemic effects[13,14]. 
   Thiazine are six member heterocyclic that contain in their structure a nitrogen and a sulfar atom. It is a very 
useful unit in the fields of medicinal and pharmaceutical chemistry and have been reported to exhibit a variety of 
biological activities such as antioxidant [15], antidyslipidemic and anti-inflammatory[16]. 
   The aim of the present study is to evaluate the effect of compounds(I and II) on CK and HMG-CoA reductase 
activities in hyperlipidemia patients. Also to determine the type of inhibition of these compounds which may be 
used as lipid lowering agents in future. 
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Material and Methods: 
   Sixty individuals with age ranged between (40-60) years were enrolled in this study. They were divided into 
groups; first group (G1) consisted of 30 healthy individuals as a control group with body mass index (BMI) 
25.67. The second group (G2) consisted of 30 patients with hyperlipidemia and BMI 26.48. The patients 
attended the Ibn-Alnaphaes hospital during November 2013 to February 2014 who they were diagnosed by 
physician as hyperlipidemia. Patients with high blood viscosity, diabetes mellitus, and renal failure as well as 
those who are under treatment with statins were excluded. 
   Ten milliliters of fasting blood were collected from all subjects. The serum obtained used in determination of 
lipid profile[total cholesterol (Tch), triglyceride (TG),  high density lipoprotein(HDL), very low density 
lipoprotein(VLDL)],fasting blood glucose(FBG),alanine transaminase(ALT),Aspartate transaminase(AST) and 
C-reactive protein(CRP) according to the standard procedures of the biochemistry laboratory of the hospital. 
   Data are presented as mean± SD. The differences between two groups were analyzed by student's t-test. P-
value of <0.05 and 0.001 considered significant and highly significant, respectively. 
   The structure of compounds I and II that used in this study as lipid lowering agent are wshowen in figure(1). 
These compounds were prepared in previous study[17]. 
 
 
Figure(1): The structure of compounds I and II 
 
Determination of Biological Activity of Compounds (I and II) as Lipid Lowering Agents: 
-Determination of CK and HMG-CoA Reductase Activities: 
   The CK activity was determined by using  a ready kit from Randox-UK by monitoring the concentration of 
creatine kinase, hexokinase and glucose-6-phosphate dehydrogenase. The absorbance was recorded at 
340nm[18]. 
HMG-CoA reductase activity was measured spectrophotometrically which HMG- 
CoA reductase, HMG-CoA and NADPH performed from Sigma Alderage. The HMG-CoA dependent on 
oxidation of NADPH. Absorbance reduction at 340nm was measured in 6min interval[19]. 
   Fourdifferent dilutions (10-2, 10-3 , 10-4 and 10-5 )M for both compounds were 
prepared from a stock solution (10-1) M in distilled water with addition of few drops of ethanol. 
   Activities of CK and HMG-CoA reductase were determined in G1 and G2 before and after addition of 
different concentrations of compound I and compound II. 
   Simvastatin, which considered as standard drug for lipid lowering, was used for comparison with the potency 
of compounds I and II on HMG-CoA reductase activity in treatment of hyperlipidemia. 
 
Determination of Km and Vmax for CK and HMG-CoA Reductase: 
   The Km and Vmax for CK and HMG-CoA Reductase were performed using different concentrations of 
substrate. 
Determination of Percentage inhibition: 
   The percentage of inhibition was determined by using different concentrations of 
compounds I and II while the concentration of substate [S]  was fixed. 
   The activity of the enzymes without addation of any compound was considered to be100% and all the results 
were relative to it. The concentration of compounds that gives the highest percentage of inhibition was used 
throughout the study to obtain the type of inhibition. 
Determination of the type of the inhibition: 
   Fixed concentrations of compounds I and II were used by utilizing the same concentrations of substrate 
without using both compounds were performed. The effect 
of solvent, which used as diluents, was determined  by adding a quantity equivalent 
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to the sample and all steps completed as in the method of determination of CK and HMG-CoA reductase 
activities. Its inhibition effect was determined and subtract from the results before determining the inhibition or 
activation of the compounds. 
 
Results and Discussion: 
   The levels of charastastic parameters in patients and control groups are summarizes in table (1). The results 
which exptressed as (mean± SD), showed highly significant elevation in Tch, TG, LDL, VLDL, ALT, AST and 
CRP while there are significant reduction in HDL levels when comparing between G1 and G2. The results, also 
showed no significant elevation in FBG level when comparing between G1 and G2. 
   Table(2 and 3) represent the activities of CK and HMG-CoA reductase, respectively,in G1 and G2 before and 
after addition of compounds I and II in different concentrations (10-2 , 10-3 ,10-4 and 10-5)M. 
   The results revealed that compound I showed inhibitory effect on CK activity at  (10-3  ,10-4 and10-5 ) M, while 
it showed activator effect for enzyme at concentrations (10-2)M. Compound II showed inhibitory effect on CK 
activity at (10-2  and 10-5) M, while it showed activator effect for enzyme at concentrations (10-3 and 10-4 )M. 
The results also revealed that compounds I and II showed inhibitory effect on HMG-CoA reductase in all 
concentrations. 
   The results demonstrated that compound I showed the best inhibition effect at 10-4 M concentration, while 
compound II showed the best inhibition effect at 10-5M concentration for both enzymes which were chosen for 
kinetic study. 
   Figure(1 and 2) showed the type of inhibition for compounds I on CK and HMG-CoA reductase activities 
using Lineweaver-Burk plot. The results revealed that compound I was found to be a noncompetitive inhibitor 
for the CK with the Vmax values(1000 and 344.82) U/L respectively for the uninhibited and inhibited 
reactionsand Km value (10) mmol/L, while compound I was found to be competitive inhibitor on HMG-CoA 
reductase with Vmax value (0.020) U/L and Km values (0.339 and 0.125) mmol/L respectively for the uninhibited 
and inhibited reactions. 
   Figure(3 and 4) showed the type of inhibition for compounds II on CK and HMG-CoA reductase activities 
using Lineweaver-Burk plot. The results revealed that compound II was found to be a competitive inhibitor for 
both enzymes with the Vmax value (588.23) U/L and Km values (5.51 and 4)M respectively for the uninhibited 
and inhibited reactions for CK and Vmax value (0.021) U/L and Km 
Values (1.111 and 0.256) mmol/L respectively for the uninhibited and inhibited reactions for HMG-CoA 
reductase. 
The activity of simvastatin on HMG-CoA reductase activity was shown in table(4).The results revealed that 
compounds I and II found to be more potent as lipid lowering agents than simvastatin. 
   Statins are the major drug to treat hyperlipidemia that are even prescribed to the healthy population, to prevent 
heart disease development. However, the statin use is an open discussion because of their side effects such as 
myostis, define as the presence of muscle symptoms, including aches, soreness, or weakness, and an increase in 
serum CK[20]. Taking into consideration that millions of people are treated with statins, a lot of them complain 
of side effects especially in high dose treatment and this suggests that,despite the success of statins, efforts in the 
development of novel hypolipidemic compounds should be needed [21]. 
   A dozen of the synthetic compounds mimic the inhibition of purified HMG-CoA redutase activity caused by 
pravastatin, fluvastatin and sodium salt of lovastatin, simvastatin in the cell free assay, suggesting direct 
interaction with the rate limiting enzyme of cholesterol biosynthesis[22]. 
   A new thiazine derivatives which was prepared by recent studies showed squalene synthase 
inhibitory/hypolipidemic activities which suggested that these compounds strongly inhibited in vitromicrosomal 
lipid and LDL peroxidation[23,24].This could be due to the affinity of such compounds to compete on binding to 
the active sites of the enzyme. 
   In conclusion the novel synthetic compounds (I and II) seem to be of interest in development of a new 
antihyperlipidemic agents that exhibit inhibition effect on CK while statins cause increasing in this enzyme. Also 
these compounds exhibit inhibition effect on HMG-CoA reductase activity more than simvastatin. 
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Table(1):Descriptive parameters in the studied groups (G1, G2) 
 
             Groups 
Parameters 
G1 
n=30 
G2 
n=30 
P* 
BMI (kg/m) 25.67±4.55 26.48±5.22 NS 
Tch (mg/dl) 121.7±13.84 458.05±71.75 <0.001 
TG (mg/dI) 97.73±5.07 199.16±53.07 <0.05 
HDL-c (mg/dI) 42.43±4.07 28.37±5.73 <0.001 
LDL-c (mg/dI) 60.36±14.15 390.68±54.58 <0.001 
VLDL-c  (mg/dI) 19.67±1.19 39.96±19.56 <0.05 
FBG (mg/dI) 95.8±17.22 96.2±9.40 NS 
ALT (U/L) 14.39±3.04 63±5.83 <0.001 
AST (U/L) 13.89±2.77 85.3±7.66 <0.001 
CRP (mg/dI) 0.40±0.16 2.99±0.11 <0.05 
              NS, No Significant 
 
Table(2): The CK activity in U/L in G1, and G2 before(B) and after(A) addition of different 
concentrations of compound I and compound II 
 
Groups HMG-CoA red. 
Activity(U) 
Compounds HMG-CoA red activity (U)in G2(A) 
10-2M 10-3M 10-4M 10-5M 
G1 85.34 Compound 
I 
340.06 208.41 175.39 229.04 
G2(B) 252.5 Compound 
II 
215.28 356.98 316.95 189.01 
 
Table(3): HMG-CoA reductase activity in U/L in G1, and G2 before(B) and after(A) addition     
of different concentrations of compound I and compound II   
 
Groups HMG-CoA red. 
Activity(U) 
Compounds HMG-CoA red activity (U)in G2(A) 
10-2M 10-3M 10-4M 10-5M 
G1       0.009 Compound 
      I 
0.020 0.020 0.012 0.020 
G2(B)        2.00 Compound 
    II 
0.021 0.019 0.023 0.017 
 
Table(4): HMG-CoA reductase activity (U) in G1, and G2 before(B) and after(A) additionof simvastatin 
 
Groups HMG-CoA reductase 
activity 
G1 0.009 
G2(B) 0.200 
G2(A) (Simvastatin) 0.024 
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